2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
7
Esophageal Neoplasms
4
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Adenocarcinoma
2
Solid Tumor
1
Rectal Neoplasms
1
Patients With Advanced or Metastatic Solid Tumors
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Carcinoma
1
Locally Advanced Gastric Adenocarcinoma
1
Hand-Foot Syndrome
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
271
Fluorouracil
268
Capecitabine
235
Leucovorin
209
Irinotecan
152
Radiotherapy
139
Bevacizumab
114
Cetuximab
82
Surgical Procedures, Operative
51
Folfox protocol
49
Neoadjuvant Therapy
45
Drug Therapy
43
Radiation
42
Chemotherapy, Adjuvant
34
Chemoradiotherapy
34
Panitumumab
27
Magnetic Resonance Spectroscopy
26
XELOX
25
Radiotherapy, Intensity-Modulated
23
Biopsy
20
Surveys and Questionnaires
18
Laparoscopy
18
Proctectomy
17
Floxuridine
17
Early Intervention, Educational
16
Nivolumab
15
Immunohistochemistry
15
Gene Expression Profiling
15
Gemcitabine
15
pembrolizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
tegafur-gimeracil-oteracil
×
Clear all
NCT02216149
2018-08-28
FluoHeart
Helsinki University Central Hospital
Phase 2
Terminated
20 enrolled